^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
palonosetron intravenous
i
Other names: RS-42358-197, RS-25259-197, RS-25259, 2-QHBIQO
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Generic mfg.
Drug class:
Serotonin 3 receptor antagonist
Related drugs:
4ms
Cisplatin Disposition and Kidney Injury (clinicaltrials.gov)
P3, N=72, Active, not recruiting, University of Colorado, Denver | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Sep 2025 --> Sep 2027
Trial completion date • Trial primary completion date
|
cisplatin • granisetron oral • ondansetron • palonosetron intravenous
4ms
Comparative Analysis of Oliceridine versus Sufentanil in Gastrointestinal Endoscopy for Geriatric Patients (ChiCTR2500103917)
P4, N=198, Not yet recruiting, Jinjiang Municipal Hospital; Jinjiang Municipal Hospital
New P4 trial
|
Sufenta (sufentanil) • palonosetron intravenous
2years
Cisplatin Disposition and Kidney Injury (clinicaltrials.gov)
P3, N=72, Recruiting, University of Colorado, Denver | Phase classification: P=N/A --> P3 | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Sep 2023 --> Sep 2025
Phase classification • Trial completion date • Trial primary completion date
|
cisplatin • granisetron oral • ondansetron • palonosetron intravenous
over2years
A221602: Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov)
P3, N=690, Completed, Alliance for Clinical Trials in Oncology | Active, not recruiting --> Completed | Trial completion date: Aug 2023 --> May 2023
Trial completion • Trial completion date
|
dexamethasone • fosaprepitant • olanzapine • ondansetron • palonosetron intravenous
Share via
